Document Detail


Pharmacokinetics of O6-benzylguanine (NSC637037) and its metabolite, 8-oxo-O6-benzylguanine.
MedLine Citation:
PMID:  12953345     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
O6-Benzylguanine and its metabolite, 8-oxo-O6-benzylguanine, are equally potent inhibitors of the DNA repair enzyme, O6-alkylguanine-DNA alkyltransferase. Pharmacokinetic values are derived from cancer patients participating in a phase I trial (10 or 20 mg/m2 of O6-benzylguanine in a single bolus dose or 10 to 120 mg/m2 as a 60-min constant infusion). A two-compartment model fits the plasma concentration versus time profile of O6-benzylguanine. O6-Benzylguanine is eliminated rapidly from the plasma compartment in humans (t1/2 alpha and t1/2 beta are 2 +/- 2 min and 26 +/- 15 min [mean +/- SD, n = 7], respectively), and its plasma clearance (513 +/- 148 mL/min/m2) is not dose dependent. Metabolite kinetics are evaluated using both a novel approach describing the relationship between O6-benzylguanine and 8-oxo-O6-benzylguanine and classical metabolite kinetics methods. With increasing doses of O6-benzylguanine, the plasma clearance of 8-oxo-O6-benzylguanine, decreases, prolonging elimination of the metabolite. This effect is not altered by coadministration of BCNU. The urinary excretion of drug and metabolites is minimal.
Authors:
Kou-Yi Tserng; Stephen T Ingalls; Erik M Boczko; Timothy P Spiro; Xiaolin Li; Susan Majka; Stanton L Gerson; James K Willson; Charles L Hoppel
Related Documents :
3439885 - The relevance of 4,5-dihydroxy-2-hexanone in the excretion kinetics of n-hexane metabol...
1122675 - Antiarrhythmic potency of n-acetylprocainamide.
22435925 - Reduced urinary glutamate levels are associated with the frequency of migraine attacks ...
6659545 - The biliary and urinary metabolites of [3h]17 alpha-ethynylestradiol in women.
3676155 - Selenium status in patients with liver cirrhosis and alcoholism.
7031155 - The effect of prostaglandin inhibition on renin release. a comparison of furosemide and...
Publication Detail:
Type:  Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Journal of clinical pharmacology     Volume:  43     ISSN:  0091-2700     ISO Abbreviation:  J Clin Pharmacol     Publication Date:  2003 Aug 
Date Detail:
Created Date:  2003-09-04     Completed Date:  2003-11-10     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  0366372     Medline TA:  J Clin Pharmacol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  881-93     Citation Subset:  IM    
Affiliation:
Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Departments of Nutrition, Medicine, Mathematics, and Pharmacology, Case Western Reserve University, Ireland Cancer Center, University Hospitals of Cleveland, Cleveland, Ohio, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Antineoplastic Agents, Alkylating / therapeutic use
Carmustine / therapeutic use
Enzyme Inhibitors / metabolism,  pharmacokinetics*,  pharmacology
Female
Guanine / analogs & derivatives*,  blood,  metabolism*,  pharmacokinetics*
Half-Life
Humans
Infusions, Intravenous
Male
Metabolic Clearance Rate
Middle Aged
Models, Biological
Neoplasms / drug therapy,  metabolism*
O(6)-Methylguanine-DNA Methyltransferase / antagonists & inhibitors
Grant Support
ID/Acronym/Agency:
2 U01 CA62502/CA/NCI NIH HHS; M01 RR-00080-36/RR/NCRR NIH HHS; P30 CA 43703/CA/NCI NIH HHS; R01 CA 75518/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/8-oxo-O(6)-benzylguanine; 0/Antineoplastic Agents, Alkylating; 0/Enzyme Inhibitors; 154-93-8/Carmustine; 73-40-5/Guanine; EC 2.1.1.63/O(6)-Methylguanine-DNA Methyltransferase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Long-term changes in mycophenolic acid exposure in combination with tacrolimus and corticosteroids a...
Next Document:  A limited sampling method for the estimation of serum calcitriol area under the curve in cancer pati...